1
|
Hu Y, Fu K, Liu H, He Q, Qiu X, Yang W, Zhang Y. Ovarian seromucinous carcinoma: an independent epithelial ovarian cancer? J Ovarian Res 2023; 16:18. [PMID: 36670456 PMCID: PMC9862510 DOI: 10.1186/s13048-023-01100-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2021] [Accepted: 01/11/2023] [Indexed: 01/21/2023] Open
Abstract
BACKGROUND 2020 World Health Organization Classification of Female Genital Tumors removed ovarian seromucinous carcinoma as a distinct entity and recategorized it as ovarian endometrioid carcinoma with mucinous differentiation according to its pathological features. The aim of this study was to find whether ovarian seromucinous carcinoma truly represented a distinct category of ovarian tumors or an analogue of ovarian endometrioid carcinoma. METHODS Twelve patients diagnosed with ovarian seromucinous carcinoma and received surgery at the Xiangya Hospital from January 2010 to December 2019 were included in this study. Clinicopathological features such as clinical symptoms, serological indicators, surgical information, postoperative findings, chemotherapy sensitivity, follow-up information, HE staining and IHC staining images and other clinicopathologic features were collected. Using t-test and Kaplan Meier to perform statistical analysis. Pathological review was conducted using the 2014 World Health Organization criteria. All pathological diagnoses were reviewed by two experienced pathologists. RESULTS The age of 12 patients diagnosed with ovarian seromucinous carcinoma ranged from 23 to 68 years, with a median age of 46.8 years. Serum level of CA125 was elevated in 10 patients, and CA125/CEA ratio was less than 25 in 6 patients. Eleven patients underwent radical ovarian cancer surgery, and one patient underwent fertility preservation surgery. The progression free survival and overall survival of ovarian seromucinous carcinoma is 46.8 months and 50.2 months. Kaplan-Meier survival curve showed that the prognosis of ovarian seromucinous carcinoma and ovarian endometrioid carcinoma was significantly different (P = 0.03). The prognosis of ovarian seromucinous carcinoma and ovarian mucinous carcinoma was similar. CONCLUSION Although ovarian seromucinous carcinoma and ovarian endometrioid carcinoma are similar in pathologic morphology, their clinical features and prognosis are significantly different. The signs, serum biomarker and prognosis of the ovarian seromucinous carcinoma are similar with ovarian mucinous carcinoma. Therefore, ovarian seromucinous carcinoma is not suitable to be directly classified as ovarian endometrioid carcinoma.
Collapse
Affiliation(s)
- Yi Hu
- grid.452223.00000 0004 1757 7615Department of Gynecology, Xiangya Hospital, Central South University, Changsha, Hunan China
| | - Kun Fu
- grid.452223.00000 0004 1757 7615Department of Gynecology, Xiangya Hospital, Central South University, Changsha, Hunan China
| | - Huining Liu
- grid.452223.00000 0004 1757 7615Department of Gynecology, Xiangya Hospital, Central South University, Changsha, Hunan China
| | - Qiongqiong He
- grid.452223.00000 0004 1757 7615Department of Pathology, Xiangya Hospital, Central South University, Hunan Changsha, China
| | - Xiaoqin Qiu
- grid.452223.00000 0004 1757 7615Department of Pathology, Xiangya Hospital, Central South University, Hunan Changsha, China ,grid.216417.70000 0001 0379 7164Department of Pathology, School of Basic Medicine, Central South University, Changsha, Hunan China
| | - Wenqing Yang
- Gynecological Oncology Research and Engineering Center of Hunan Province, 86 Xiangya Road, Changsha, Hunan 410018 China
| | - Yu Zhang
- Gynecological Oncology Research and Engineering Center of Hunan Province, 86 Xiangya Road, Changsha, Hunan 410018 China
| |
Collapse
|
2
|
Yu N, Li X, Yang B, Chen J, Wu MF, Wei JC, Li KZ. Clinical characteristics and survival of patients with normal-sized ovarian carcinoma syndrome: Retrospective analysis of a single institution 10-year experiment. World J Clin Cases 2020; 8:5116-5127. [PMID: 33269248 PMCID: PMC7674751 DOI: 10.12998/wjcc.v8.i21.5116] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/28/2020] [Revised: 08/16/2020] [Accepted: 10/01/2020] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND Normal size ovarian cancer syndrome (NOCS) is a challenge for clinicians regarding timely diagnosis and management due to atypical clinical and imaging features. It is extremely rare with only a few cases reported in the literature. More data are needed to clarify its biological behavior and compare the differences with abnormal size ovarian cancer.
AIM To assess the clinical and pathological features of NOCS patients treated in our institution in the last 10 years and to explore risk factors for relapse and survival.
METHODS Patients who were pathologically diagnosed with NOCS between 2008 and 2018 were included. Papillary serous ovarian carcinoma (PSOC) patients were initially randomly recruited as the control group. Demographics, tumor characteristics, treatment procedures, and clinical follow-up were retrospectively collected. Risk factors for progression-free survival and overall survival were assessed.
RESULTS A total of 110 NOCS patients were included; 80 (72.7%) had primary adnexal carcinoma, two (1.8%) had mesotheliomas, 18 (16.4%) had extraovarian peritoneal serous papillary carcinoma, and eight (7.3%) had metastatic tumors. Carbohydrate antigen (CA)125 and ascites quantity were lower in the NOCS cohort than in the PSOC group. The only statistically significant risk factors for worse overall survival (P < 0.05) were the levels of CA199 and having fewer than six chemotherapy cycles. The 1-year, 3-year, and 5-year survival rates were 75.5%, 27.7%, and 13.8%, respectively.
CONCLUSION The clinical symptoms of the NOCS group are atypical, and the misdiagnosis rate is high. Ascites cytology and laparoscopic exploration are valuable in the early diagnosis to avoid a misdiagnosis. The level of CA199 is the most important predictor of overall survival, and more than six cycles of chemotherapy contributes to the increased survival rates of NOCS patients.
Collapse
Affiliation(s)
- Nan Yu
- Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
| | - Xi Li
- Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
| | - Bin Yang
- Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
| | - Jing Chen
- Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
| | - Ming-Fu Wu
- Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
| | - Jun-Cheng Wei
- Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
| | - Ke-Zhen Li
- Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
| |
Collapse
|
3
|
Choi MC, Hwang S, Kim S, Jung SG, Park H, Joo WD, Song SH, Lee C, Kim TH, Kang H, An HJ. Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma. Cancer Res Treat 2020; 52:634-644. [PMID: 32019284 PMCID: PMC7176973 DOI: 10.4143/crt.2019.207] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2019] [Accepted: 01/02/2020] [Indexed: 01/23/2023] Open
Abstract
Purpose In this study, we investigated the frequencies of mutations in DNA damage repair genes including BRCA1, BRCA2, homologous recombination genes and TP53 gene in ovarian high-grade serous carcinoma, alongside those of germline and somatic BRCA mutations, with the aim of improving the identification of patients suitable for treatment with poly(ADP-ribose) polymerase inhibitors. Materials and Methods Tissue samples from 77 Korean patients with ovarian high-grade serous carcinoma were subjected to next-generation sequencing. Pathogenic alterations of 38 DNA damage repair genes and TP53 gene and their relationships with patient survival were examined. Additionally, we analyzed BRCA germline variants in blood samples from 47 of the patients for comparison. Results BRCA1, BRCA2, and TP53 mutations were detected in 28.6%, 5.2%, and 80.5% of the 77 patients, respectively. Alterations in RAD50, ATR, MSH6, MSH2, and FANCA were also identified. At least one mutation in a DNA damage repair gene was detected in 40.3% of patients (31/77). Germline and somatic BRCA mutations were found in 20 of 47 patients (42.6%), and four patients had only somatic mutations without germline mutations (8.5%, 4/47). Patients with DNA damage repair gene alterations with or without TP53 mutation, exhibited better disease-free survival than those with TP53 mutation alone. Conclusion DNA damage repair genes were mutated in 40.3% of patients with high-grade serous carcinoma, with somatic BRCA mutations in the absence of germline mutation in 8.5%. Somatic variant examination, along with germline testing of DNA damage repair genes, has potential to detect additional candidates for PARP inhibitor treatment.
Collapse
Affiliation(s)
- Min Chul Choi
- Department of Obstetrics and Gynecology, Comprehensive Gynecologic Cancer Center, CHA University, Seongnam, Korea.,Center for Cancer Precision Medicine, CHA University, Seongnam, Korea
| | - Sohyun Hwang
- Center for Cancer Precision Medicine, CHA University, Seongnam, Korea.,Department of Pathology, CHA Bundang Medical Center, CHA University, Seongnam, Korea
| | - Sewha Kim
- Department of Pathology, CHA Bundang Medical Center, CHA University, Seongnam, Korea
| | - Sang Geun Jung
- Department of Obstetrics and Gynecology, Comprehensive Gynecologic Cancer Center, CHA University, Seongnam, Korea
| | - Hyun Park
- Department of Obstetrics and Gynecology, Comprehensive Gynecologic Cancer Center, CHA University, Seongnam, Korea
| | - Won Duk Joo
- Department of Obstetrics and Gynecology, Comprehensive Gynecologic Cancer Center, CHA University, Seongnam, Korea
| | - Seung Hun Song
- Department of Obstetrics and Gynecology, Comprehensive Gynecologic Cancer Center, CHA University, Seongnam, Korea
| | - Chan Lee
- Center for Cancer Precision Medicine, CHA University, Seongnam, Korea
| | - Tae-Heon Kim
- Center for Cancer Precision Medicine, CHA University, Seongnam, Korea.,Department of Pathology, CHA Bundang Medical Center, CHA University, Seongnam, Korea
| | - Haeyoun Kang
- Center for Cancer Precision Medicine, CHA University, Seongnam, Korea.,Department of Pathology, CHA Bundang Medical Center, CHA University, Seongnam, Korea
| | - Hee Jung An
- Center for Cancer Precision Medicine, CHA University, Seongnam, Korea.,Department of Pathology, CHA Bundang Medical Center, CHA University, Seongnam, Korea
| |
Collapse
|
4
|
Yan J, Zhang Y, Shi W, Ren C, Liu Y, Pan Y. The critical role of HMGA2 in regulation of EMT in epithelial ovarian carcinomas. Tumour Biol 2015; 37:823-8. [PMID: 26250458 DOI: 10.1007/s13277-015-3852-x] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2015] [Accepted: 07/28/2015] [Indexed: 01/19/2023] Open
Abstract
The high mobility group A2 (HMGA2), an oncofetal protein, was shown to play a role in tumor development and progression. However, the molecular and clinical role of HMGA2 in epithelial ovarian carcinomas (EOCs) is still unknown. In the present study, EOC cell line SKOV3 was subjected to in vitro assays. Here, our findings showed that HMGA2 was highly expressed in EOC cell line SKOV3. HMGA2 knockdown promoted cell apoptosis and the cleavage of caspase 3, and decreased the B cell lymphoma 2 (Bcl-2)/Bax ratio in SKOV3. Functionally, HMGA2 knockdown resulted in reduction of SKOV3 cell migration and invasion. Mechanically, HMGA2 knockdown affected the occurrence of EMT by increasing E-cadherin gene and protein expression and decreasing the gene and protein expression of N-cadherin, slug, and vimentin. At the same time, HMGA2 also repressed the expression of matrix metalloproteinase 2 (MMP2) and matrix metalloproteinase 9 (MMP9), which was consistent with the decreased invasion capacity. In conclusion, HMGA2 is associated with migration and invasiveness and regulates the progression of EMT in the development of EOC, and HMGA2 gene and protein may be a novel therapeutic target against EOC in the clinical practice.
Collapse
Affiliation(s)
- Junyuan Yan
- Department of Gynaecology and Obstetrics, Affiliated Hospital of Shandong Academy of Medical Sciences, 38# Wuyingshan Road, 250031, Jinan, Shandong, China
| | - Yanling Zhang
- Department of Gynaecology and Obstetrics, The Third People's Hospital of Jinan City, Jinan, Shandong, China
| | - Wenshuang Shi
- Department of Gynaecology and Obstetrics, The Third People's Hospital of Jinan City, Jinan, Shandong, China
| | - Cuili Ren
- Department of Gynaecology and Obstetrics, The Third People's Hospital of Jinan City, Jinan, Shandong, China
| | - Yan Liu
- Department of Gynaecology and Obstetrics, Affiliated Hospital of Shandong Academy of Medical Sciences, 38# Wuyingshan Road, 250031, Jinan, Shandong, China
| | - Yunyan Pan
- Department of Gynaecology and Obstetrics, Affiliated Hospital of Shandong Academy of Medical Sciences, 38# Wuyingshan Road, 250031, Jinan, Shandong, China.
| |
Collapse
|
5
|
Ciucci A, Zannoni GF, Travaglia D, Petrillo M, Scambia G, Gallo D. Prognostic significance of the estrogen receptor beta (ERβ) isoforms ERβ1, ERβ2, and ERβ5 in advanced serous ovarian cancer. Gynecol Oncol 2013; 132:351-9. [PMID: 24378878 DOI: 10.1016/j.ygyno.2013.12.027] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2013] [Revised: 12/11/2013] [Accepted: 12/18/2013] [Indexed: 11/18/2022]
Abstract
OBJECTIVE In the present study we have examined the pattern of expression of the full length estrogen receptor β (ERβ1) and two ERβ splice variant isoforms (ERβ2, ERβ5) in well-characterized advanced serous ovarian cancers. METHODS Immunohistochemistry was performed with ERβ1, ERβ2, and ERβ5 antibodies and results were correlated with pathological and clinical follow-up data. Expression of ERβ isoforms in a panel of ovarian cancer cell lines and human tumor xenografts was also assessed. RESULTS Immunohistochemical staining revealed cellular compartment-specific distribution for each isoform in malignant ovarian tissues exhibiting both nuclear staining and cytoplasmic staining. Patients with cytoplasmic ERβ2 expression had significantly worse outcome (p = 0.006 at the multivariate analysis), the 5-year survival rate being nearly 28% for patients who did express cytoplasmic ERβ2, and 60% in negative patients. Cytoplasmic ERβ2 expression was also found to be significantly associated with chemoresistance. In concordance with clinical results both nuclear and cytoplasmic expressions were observed for the three isoforms in the cancer cell lines and human tumor xenografts tested. CONCLUSIONS This is the first study to uncover an unfavorable prognostic role of ERβ2 in advanced serous ovarian cancer. If anomalies of ERβ2 cytoplasmic expression could be demonstrated to represent an independent unfavorable prognostic marker and/or a marker predicting chemoresistance in advanced serous ovarian cancer, its immunohistochemical assessment at the time of surgery, could help to recognize candidates for clinical trials of new interventions.
Collapse
Affiliation(s)
- Alessandra Ciucci
- Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy
| | - Gian Franco Zannoni
- Department of Histopathology, Catholic University of the Sacred Heart, Rome, Italy
| | - Daniele Travaglia
- Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy
| | - Marco Petrillo
- Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy
| | - Giovanni Scambia
- Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy
| | - Daniela Gallo
- Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy.
| |
Collapse
|